SCHEMBL3409853

SCHEMBL3409853

O=C(O)C(CO)Oc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PPARG P37231 20/20 0.59
PPARA Q07869 18/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8024661 0.86 PPARG (0.49) PPARGPPARA
SCHEMBL28417484 0.85 PPARG (0.61) PPARGPPARA
SCHEMBL940490 0.84 PPARG (0.58) PPARGPPARA
SCHEMBL10735245 0.83 PPARG (0.44) PPARGPPARA
SCHEMBL21057234 0.82 LDHA (0.61) PPARGPPARA
SCHEMBL21057232 0.82 LDHA (0.61) PPARGPPARA
SCHEMBL1874697 0.82 PPARG (0.70) PPARGPPARA
SCHEMBL4651839 0.82 SMN1; SMN2 (0.64) PPARGPPARA
SCHEMBL11501300 0.82 PPARG (0.57) PPARGPPARA
SCHEMBL4300663 0.82 PPARG (0.58) PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025264177-A1 METHOD FOR CLEAVING PROTECTING GROUPS AND ORGANIC COMPOUNDS FROM SUPPORTS POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) 2025-12-26 WO claimed
US-20180259510-A1 NON-COVALENT PATTERNED CHEMICAL FEATURES AND USE THEREOF IN MALDI-BASED QUALITY CONTROL NATIONAL SCIENCE FOUNDATION 2018-09-13 US claimed
US-20160041158-A1 NON-CONVALENT PATTERNED CHEMICAL FEATURES AND USE THEREOF IN MALDI-BASED QUALITY CONTROL NATIONAL SCIENCE FOUNDATION 2016-02-11 US claimed
CN-103314010-B Solid phase synthesis of h(gly2)glp-2 NYCOMED GMBH 2015-03-04 CN claimed
WO-2014144383-A1 NON-COVALENT PATTERNED CHEMICAL FEATURES AND USE THEREOF IN MALDI-BASED QUALITY CONTROL ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2014-09-18 WO claimed
CN-103314010-A Solid phase synthesis of h(gly2)glp-2 NYCOMED GMBH 2013-09-18 CN claimed
EP-1679318-A1 Process for folding chemically synthesized polypeptides RMF DICTAGENE S.A. (CH) 2006-07-12 EP claimed
EP-1337549-B1 PROCESS FOR FOLDING CHEMICALLY SYNTHESIZED POLYPEPTIDES RMF DICTAGENE SA (CH) 2006-04-05 EP claimed
US-20050239162-A1 Process for folding chemically synthesized polypeptides RMF DICTAGENE S.A. (CH) 2005-10-27 US claimed
EP-1337549-A2 PROCESS FOR FOLDING CHEMICALLY SYNTHESIZED POLYPEPTIDES RMF DICTAGENE S.A. (CH) 2003-08-27 EP claimed
WO-2002053578-A2 NOVEL APPLICATIONS FOR AN ANION EXCHANGE RESIN (EPM-8) CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTIFICO E TECNOLOGICO - CNPQ (BR) 2002-07-11 WO claimed
WO-2002050099-A2 PROCESS FOR FOLDING CHEMICALLY SYNTHESIZED POLYPEPTIDES RMF DICTAGENE S.A. (CH) 2002-06-27 WO claimed
US-20020082384-A1 Process for folding chemically synthesized polypeptides RMF DICTAGENE S.A. (CH) 2002-06-27 US claimed
US-5286789-A Clear polystyrene functionalized with linking groups APPLIED IMMUNE SCIENCES, INC. (US) 1994-02-15 US claimed
WO-2025264177-A1 METHOD FOR CLEAVING PROTECTING GROUPS AND ORGANIC COMPOUNDS FROM SUPPORTS POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) 2025-12-26 WO disclosed
US-20250282825-A1 NOVEL CYCLIC COMPOUNDS, METHOD FOR THEIR PREPARATION AND THE USE OF SAID CYCLIC COMPOUNDS IN COSMETIC PREPARATIONS EBERHARD KARLS UNIVERSITAET TUEBINGEN (DE) 2025-09-11 US disclosed
CN-110662759-B Tumor targeting peptide variants 癌症研究技术有限公司 2024-03-08 CN disclosed
EP-0400920-A1 Solid phase multiple peptide synthesis RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1990-12-05 EP disclosed
EP-0352560-A1 Novel peptides KAO CORPORATION (JP) 1990-01-31 EP disclosed
US-4508541-A DETERGENTS TEXACO INC. (US) 1985-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282825-A1 NOVEL CYCLIC COMPOUNDS, METHOD FOR THEIR PREPARATION AND THE USE OF SAID CYCLIC COMPOUNDS IN COSMETIC PREPARATIONS ODC1, NISCH, CUTA PPARG 208/4885PPARA 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.